Combining Immunotherapy and Chemotherapy in Patients With SCLC

Video

Julie R. Brahmer, MD, discusses data for atezolizumab plus platinum/etoposide versus platinum/etoposide alone in patients with small cell lung cancer in the IMpower133 trial.

Julie R. Brahmer, MD, co-director of the Upper Aerodigestive Department in the Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins Medicine, discusses data for atezolizumab (Tecentriq) plus carboplatin/etoposide versus carboplatin/etoposide alone in patients with small cell lung cancer (SCLC) in the IMpower133 trial.

Brahmer says these data showed that the addition of the immunotherapy improved progression-free survival in these patients. However, it did not improve the response rate.

Recent Videos
Efficacy and Safety Outcomes Support Approval of Cabozantinib in NETs
Efficacy and Safety Outcomes Support Approval of Cabozantinib in NETs
Dietary Recommendations for Cancer Prevention and Supportive Care
Dietary Recommendations for Cancer Prevention and Supportive Care
Ropeginterferon Alfa Reduces JAK2 Allele Burden Over Long Term in PV
Ropeginterferon Alfa Reduces JAK2 Allele Burden Over Long Term in PV
DeFi Trial Update Shows Nirogacestat's Efficacy in Desmoid Tumors
DeFi Trial Update Shows Nirogacestat's Efficacy in Desmoid Tumors
Discussing Upcoming Data and Key Takeaways in Head and Neck Cancer
Discussing Upcoming Data and Key Takeaways in Head and Neck Cancer
Long-Term Data on IO/IO in RCC Shows Intriguing Results for Favorable Risk
Long-Term Data on IO/IO in RCC Shows Intriguing Results for Favorable Risk
Gadgeel on MARIPOSA Trial Updates in EGFR+ NSCLC
Gadgeel on MARIPOSA Trial Updates in EGFR+ NSCLC
Girard Shares Early COCOON Data of Amivantamab/Lazertinib in EGFR+ NSCLC
Girard Shares Early COCOON Data of Amivantamab/Lazertinib in EGFR+ NSCLC
Recent Failures Spur Innovation in Head and Neck Cancer Trials
Recent Failures Spur Innovation in Head and Neck Cancer Trials
SUNLIGHT Findings Emphasize Role of VEGF Inhibition in Refractory CRC
SUNLIGHT Findings Emphasize Role of VEGF Inhibition in Refractory CRC
Related Content
Ocular Events With Mirvetuximab Show No Impact on QoL in Ovarian Cancer

Ocular Events With Mirvetuximab Show No Impact on QoL in Ovarian Cancer

Jordyn Sava
March 31st 2025
Article

Read More

FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC

FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC

Jordyn Sava;Joshua K. Sabari, MD
March 15th 2024
Podcast

In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.

Listen

Cema-Cel Advances CAR T Therapy for LBCL in ALPHA Trials

Cema-Cel Advances CAR T Therapy for LBCL in ALPHA Trials

Jordyn Sava
March 28th 2025
Article

Frederick L. Locke, MD, discussed cema-cel's safety, efficacy, and potential for treating large B-cell lymphoma in earlier lines in the ALPHA trials.

Read More

Lisberg Discusses Dato-DXd's Role in Advanced Lung Cancer Care

Lisberg Discusses Dato-DXd's Role in Advanced Lung Cancer Care

Jordyn Sava;Aaron Lisberg, MD
December 15th 2023
Podcast

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.

Listen

Teclistamab, Daratumumab, Pomalidomide Is Feasible in Multiple Myeloma

Teclistamab, Daratumumab, Pomalidomide Is Feasible in Multiple Myeloma

Jordyn Sava
March 22nd 2025
Article

Anita D'Souza, MD, discussed the results from the MajesTEC-2 and TRIMM-2 trials in patients with multiple myeloma.

Read More

Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond

Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond

Jonah Feldman
March 21st 2025
Article

Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.

Read More